IP Library › Granted Patent US 12,655,161
Granted Patent B2
US 12,655,161 · App. 18/268,795 · Granted Jun 16, 2026

Solid forms of an eIF4E inhibitor

Inventors: Kapildev Kashmirilal Arora (Niantic, CT); Wesley Dewitt Clark (Gales Ferry, CT); David Malcolm Crowe (Boothwyn, PA); Jason Gray (Boothwyn, PA)
Assignees: Pfizer Inc.; eFFECTOR Therapeutics Inc.
C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,655,161
App. No.
18/268,795
Granted
Jun 16, 2026
Kind
B2
Abstract

The present invention relates to solid forms of 7-(5-chloro-2-(3-(5-cyano-6-((1-(3,3-difluorocyclobutyl)piperidin-4-yl)(methyl)amino)-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)prop-1-yn-1-yl)phenyl)-N-(methylsulfonyl)thieno[3,2-b]pyridine-3-carboxamide, to pharmaceutical compositions comprising such solid forms, and to methods of using such solid forms and pharmaceutical compositions for the treatment of cancer.

Claims (9)

1 . A crystalline form of 7-(5-chloro-2-(3-(5-cyano-6-((1-(3,3-difluorocyclobutyl)piperidin-4-yl)(methyl)amino)-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl) prop-1-yn-1-yl)phenyl)-N-(methylsulfonyl) thieno[3,2-b]pyridine-3-carboxamide hydrate, having a powder X-ray diffraction (PXRD) pattern comprising peaks at 2θ values of: 7.8, 6.4, and 5.2° 2θ±0.2° 2θ.

2 . The crystalline form of claim 1 , having a PXRD pattern further comprising a peak at a 2θ value of: 17.2° 2θ±0.2° 2θ.

3 . The crystalline form of claim 1 , having a Raman spectrum comprising wavenumber (cm −1 ) values of: 1694 and 1680 cm −1 ±2 cm −1 .

4 . The crystalline form of claim 1 , having a 13 C solid state NMR spectrum comprising resonance (ppm) values of: 47.3, 125.4, and 153.6 ppm±0.2 ppm.

5 . The crystalline form of claim 1 , having a 1° F. solid state NMR spectrum comprising resonance (ppm) values of: −93.2 and −80.4 ppm±0.2 ppm.

6 . The crystalline form of claim 2 , wherein said crystalline form is further characterized as having a 13 C solid state NMR spectrum comprising resonance (ppm) values of: 47.3, 125.4, and 153.6 ppm±0.2 ppm.

7 . The crystalline form of claim 2 , wherein said crystalline form is further characterized as having a 19 F solid state NMR spectrum comprising resonance (ppm) values of: −93.2 and −80.4 ppm±0.2 ppm.

8 . A pharmaceutical composition comprising the crystalline form of claim 1 , and a pharmaceutically acceptable carrier or excipient.

9 . A method of treating breast cancer in a subject, the method comprising administering to the subject in need thereof, a therapeutically effective amount of the crystalline form of claim 1 .

Assignments (1)
SECURITY INTEREST Recorded Jul 25, 2024
From: EFFECTOR THERAPEUTICS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 068086/0538 →
Continuity (2)
Provisional Application 63129170 · Dec 22, 2020
Related Publication 20240076301A1 · Mar 7, 2024
References Cited (17)
US 6106864A · Dolan et al. · 2000 [cited by applicant]
US 11286268B1 · Sperry · 2022 [cited by examiner]
US 20150005340A1 · Gong · 2015 [cited by applicant]
CN 114269756A · 2022 [cited by applicant]
WO 0035298A1 · 2000 [cited by applicant]
WO 2014179237A1 · 2014 [cited by applicant]
WO WO2021003157A1 · 2021 [cited by examiner]
WO 2022137174A1 · 2022 [cited by applicant]
Hsieh, Clin. Cancer Res.; 16(20), 2010 (Year: 2010). [cited by examiner]
Pettersson, Expert Opin. Ther. Targets, 2014, 18(9) (Year: 2014). [cited by examiner]
Eisenhauer et al. (2009) “New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (version 1.1)”, European Journal of Cancer, 45(2):228-247. [cited by applicant]
Giri et al. (2010) “Synthesis and Evaluation of Quinazolinone Derivatives as Inhibitors of NF-kappaB, AP-1 Mediated Transcription and eIF-4E Mediated Translational Activation: Inhibitors of Multi-Pathways Involve in Can… [cited by applicant]
Liang et al. (2001) “Fast-Dissolving Intraoral Drug Delivery Systems”, Expert Opinion on Therapeutic Patents, 11(6):981-986. [cited by applicant]
Liu et al. (Apr. 29, 2010) “Selective Inhibition of IDO1 Effectively Regulates Mediators of Antitumor Immunity”, Blood, 115(17):3520-3530. [cited by applicant]
Rörsch et al. (Apr. 26, 2012) “Structure-Activity Relationship of Nonacidic Quinazolinone Inhibitors of Human Microsomal Prostaglandin Synthase 1 (mPGES 1)”, Journal of Medicinal Chemistry, 55(8):3792-3803. [cited by applicant]
Terentis et al. (Dec. 15, 2009) “The Selenazal Drug Ebselen Potently Inhibits Indoleamine 2,3-Dioxygenase by Targeting Enzyme Cysteine Residues”, Biochemistry, 49(3):591-600. [cited by applicant]
Verma et al. (2001) “Current Status of Drug Delivery Technologies and Future Directions”, Pharmaceutical Technology On-Line, 25:1-14. [cited by applicant]